LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization

Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma

(2021) Giulia Agliardi et al.   Nature Communications

EMP3 mediates glioblastoma‐associated macrophage infiltration to drive T cell exclusion

(2021) Qun Chen et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling

(2020) Minhai Dong et al.   CANCER GENE THERAPY

Ectosomal PKM2 Promotes HCC by Inducing Macrophage Differentiation and Remodeling the Tumor Microenvironment

(2020) Pei-pei Hou et al.   MOLECULAR CELL

Human chimeric antigen receptor macrophages for cancer immunotherapy

(2020) Michael Klichinsky et al.   NATURE BIOTECHNOLOGY

Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity

(2020) Christina A. von Roemeling et al.   Nature Communications

Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity

(2020) Lu Cui et al.   Nature Communications

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis

(2020) Jinyang Hu et al.   Frontiers in Immunology

Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2019) Anoop P Patel et al.   LANCET NEUROLOGY

CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy

(2019) Amira A. Barkal et al.   NATURE

The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma

(2019) Fangling Cheng et al.   Frontiers in Oncology

ADAM17: An Emerging Therapeutic Target for Lung Cancer

(2019) Saad et al.   Cancers

Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma

(2018) Hirokazu Sadahiro et al.   CANCER RESEARCH

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

(2018) Karolina Woroniecka et al.   CLINICAL CANCER RESEARCH

SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy

(2018) André Veillette et al.   TRENDS IN IMMUNOLOGY

Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma

(2018) Xing Song et al.   EBioMedicine

Targeting macrophages: therapeutic approaches in cancer

(2018) Luca Cassetta et al.   NATURE REVIEWS DRUG DISCOVERY

PRMT2 links histone H3R8 asymmetric dimethylation to oncogenic activation and tumorigenesis of glioblastoma

(2018) Feng Dong et al.   Nature Communications

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

(2017) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

LRIG proteins in glioma: Functional roles, molecular mechanisms, and potential clinical implications

(2017) Feng Mao et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma

(2017) Humsa S. Venkatesh et al.   NATURE

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors

(2017) Sharareh Gholamin et al.   Science Translational Medicine

Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma

(2017) Spyros Darmanis et al.   Cell Reports

A Cell-Surface Membrane Protein Signature for Glioblastoma

(2017) Dhimankrishna Ghosh et al.   Cell Systems

GlioVis data portal for visualization and analysis of brain tumor expression datasets

(2016) Robert L. Bowman et al.   NEURO-ONCOLOGY

Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals

(2015) Xudong Wu et al.   CELL RESEARCH

Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms

(2015) M. Cioffi et al.   CLINICAL CANCER RESEARCH

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization

(2015) Jason H. Stafford et al.   NEURO-ONCOLOGY

Soluble LRIG2 Ectodomain Is Released from Glioblastoma Cells and Promotes the Proliferation and Inhibits the Apoptosis of Glioblastoma Cells In Vitro and In Vivo in a Similar Manner to the Full-Length LRIG2

(2014) Qungen Xiao et al.   PLoS One

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

(2013) Stephanie M Pyonteck et al.   NATURE MEDICINE

The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status

(2013) Mikael Johansson et al.   NEURO-ONCOLOGY

Lrig2-Deficient Mice Are Protected against PDGFB-Induced Glioma

(2013) Veronica Rondahl et al.   PLoS One

miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma

(2013) L. K. Mathew et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cell Surface Receptor FPR2 Promotes Antitumor Host Defense by Limiting M2 Polarization of Macrophages

(2012) Y. Liu et al.   CANCER RESEARCH

Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1

(2010) Wei Yi et al.   EXPERIMENTAL CELL RESEARCH

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL